Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Senior Vice President and CFO | February 21, 2020 | February 25, 2020 |
| TENAX THERAPEUTICS, INC.TENX · Entity 979 | Chief Financial Officer | September 11, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date February 21, 2020 · Filed February 25, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.13 · Expires 2024-12-22 | Direct | 18,000 |
Reported balance
After 2020-02-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-21 · Grant · Acquired 18,000 · Balance 18,000 F1: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested.
TENAX THERAPEUTICS, INC.
Report date September 11, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,675 |
Reported balance
After 2026-09-11 transaction · row 1
1 source rowRow 1 · 2026-09-11 · Purchase · Acquired 5,675 · Balance 15,675 F1: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2036-05-11 | Direct | 450,000 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 450,000 F2: The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $1.90 to $1.95. The price reported in Column 4 is a weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.
F2: The options vest and become exercisable as follows: 25% vest on May 11, 2027, and thereafter, the remainder vest in substantially equal installments on each monthly anniversary of the grant date for a period of 36 months, subject to the Reporting Person's continued employment.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LENSAR, Inc.
Report date May 06, 2026 · Filed May 08, 2026
Section 16 reporting ended · disclosed 2026-05-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 174,609 |
Reported balance
After 2026-05-06 transaction · row 1
1 source rowRow 1 · 2026-05-06 · Tax withholding · Disposed 1,350 · Balance 174,609 F1: Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations incident to vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 972 | $7.26 | $7,056.72 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 6 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F4 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.25 to $7.26. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 972 | $3.22 | $3,129.84 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 5 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 5,528 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · derivative · entry 10 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,899 Underlying: Common Stock · 5,528 shares Expires 2026-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · derivative · entry 9 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,555 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 5,528 | $7.27 | $40,188.56 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F3 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.25 to $7.32. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 5,528 | $3.22 | $17,800.16 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,250 | $7.19 | $23,367.50 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $7.10 to $7.32. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 17:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-18-029520 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 17, 2018. Read SEC document |
| January 20, 2018 Filed Jan 23, 2018 14:06 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 3,979 | $5.59 | $22,242.61 |
DisclosureSEC source: 0001127602-18-002230 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,383 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 14:02 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 852 | $4.91 | $4,183.32 |
DisclosureSEC source: 0001127602-18-000299 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,362 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2015. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 15:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-17-035397 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-12-20 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 19:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-17-026936 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2024-12-22 F1 · date: On August 30, 2017, the Science Committee of the Board of Directors determined that the BCX7353 APeX-1 clinical trial met its goals and BCX7353 warrants further development. As a result, on August 31, 2017, the Compensation Committee of the Board of Directors determined that one of the vesting criteria associated with the performance-based stock options awarded in December 2014 to all employees, excluding the Chief Executive Officer, has been met. Therefore, 30% of the performance-based stock options vested on August 31, 2017. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 7,750 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001127602-17-019287 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 7,750 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 6,996 | $5.24 | $36,659.04 |
DisclosureSEC source: 0001127602-17-019287 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,214 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| May 22, 2017 Filed May 24, 2017 20:33 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 7,750 | $4.73 | $36,657.50 |
DisclosureSEC source: 0001127602-17-019287 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 14:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-012591 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,805 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 14:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,250 | $9.20 | $29,900.00 |
DisclosureSEC source: 0001127602-17-012591 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,460 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 20, 2017 Filed Mar 22, 2017 14:40 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-17-012591 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · derivative · entry 5 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 12,500 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 23,955 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · derivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,055 Underlying: Common Stock · 23,955 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 12,308 | $8.80 | $108,310.40 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,460 F1 · security: Shares of Common Stock delivered to the Company to satisfy payment of exercise price in connection with stock option exercise. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 12,500 | $1.42 | $17,750.00 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2017 Filed Mar 20, 2017 19:01 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 23,955 | $3.78 | $90,549.90 |
DisclosureSEC source: 0001127602-17-012348 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 17:47 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-011528 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,010 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 17:47 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,250 | $9.06 | $29,445.00 |
DisclosureSEC source: 0001127602-17-011528 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,313 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $9.02 to $9.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| March 10, 2017 Filed Mar 14, 2017 17:47 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-17-011528 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-011240 · form4.xml · derivative · entry 4 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,260 Underlying: Common Stock · 6,500 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,250 | $8.65 | $28,112.50 |
DisclosureSEC source: 0001127602-17-011240 · form4.xml · nonDerivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,313 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,250 | $8.20 | $26,650.00 |
DisclosureSEC source: 0001127602-17-011240 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,563 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 21:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 6,500 | $3.78 | $24,570.00 |
DisclosureSEC source: 0001127602-17-011240 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 13:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-17-010729 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,760 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 13:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,250 | $7.90 | $25,675.00 |
DisclosureSEC source: 0001127602-17-010729 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,313 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 13:05 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-17-010729 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,563 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:46 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $5.51 | $0.00 |
DisclosureSEC source: 0001127602-17-009091 · form4.xml · derivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-02-27 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 14:20 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 5,198 | $5.95 | $30,928.10 |
DisclosureSEC source: 0001127602-17-002246 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,313 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's federal and state tax withholding obligations upon the vesting of restricted stock units granted in 2014. Read SEC document |
| January 01, 2017 Filed Jan 3, 2017 19:03 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Tax withholdingCommon Stock | 1,676 | $6.33 | $10,609.08 |
DisclosureSEC source: 0001127602-17-000063 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,511 F1 · shares: Shares withheld by BioCryst Pharmaceuticals, Inc. to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2013 and 2015. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 15:42 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 3,250 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001127602-16-070634 · form4.xml · derivative · entry 3 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,010 Underlying: Common Stock · 3,250 shares Expires 2021-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 15:42 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 3,250 | $7.45 | $24,212.50 |
DisclosureSEC source: 0001127602-16-070634 · form4.xml · nonDerivative · entry 2 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,187 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 15:42 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 3,250 | $3.78 | $12,285.00 |
DisclosureSEC source: 0001127602-16-070634 · form4.xml · nonDerivative · entry 1 STAAB THOMAS R II · CIK 0001230708 · Senior Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,437 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.